Inspire Investing LLC Takes Position in Medpace Holdings, Inc. $MEDP

Inspire Investing LLC bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, HoldingsChannel reports. The firm bought 4,647 shares of the company’s stock, valued at approximately $2,610,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Optiver Holding B.V. acquired a new position in Medpace during the third quarter valued at approximately $27,000. Steigerwald Gordon & Koch Inc. acquired a new position in shares of Medpace during the 4th quarter worth approximately $30,000. Elyxium Wealth LLC acquired a new position in shares of Medpace during the 4th quarter worth approximately $30,000. Quarry LP bought a new stake in shares of Medpace during the 3rd quarter worth approximately $35,000. Finally, Core Wealth Advisors LLC bought a new stake in shares of Medpace during the 4th quarter worth approximately $47,000. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Weiss Ratings lowered shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. BMO Capital Markets decreased their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Robert W. Baird lowered their price objective on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Finally, Barclays dropped their target price on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a report on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Medpace currently has an average rating of “Hold” and an average price target of $467.08.

Medpace Trading Down 1.0%

Shares of NASDAQ MEDP opened at $457.09 on Thursday. Medpace Holdings, Inc. has a 12 month low of $294.07 and a 12 month high of $628.92. The stock has a 50 day moving average of $454.30 and a 200-day moving average of $500.75. The company has a market capitalization of $13.05 billion, a P/E ratio of 28.73, a P/E/G ratio of 2.34 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. During the same period in the previous year, the firm earned $3.67 EPS. The firm’s revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Insider Activity at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 20.50% of the stock is currently owned by corporate insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.